BR112017026142A2 - composições e métodos para tratar doença sprue celíaca - Google Patents

composições e métodos para tratar doença sprue celíaca

Info

Publication number
BR112017026142A2
BR112017026142A2 BR112017026142A BR112017026142A BR112017026142A2 BR 112017026142 A2 BR112017026142 A2 BR 112017026142A2 BR 112017026142 A BR112017026142 A BR 112017026142A BR 112017026142 A BR112017026142 A BR 112017026142A BR 112017026142 A2 BR112017026142 A2 BR 112017026142A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
sequence
celiac sprue
treating celiac
Prior art date
Application number
BR112017026142A
Other languages
English (en)
Inventor
Elaine Tinberg Christine
Wolf Clancey
Baker David
Swanson Pultz Ingrid
Bloomfield Siegel Justin
Stewart Lance
Original Assignee
Univ California
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Univ Washington filed Critical Univ California
Publication of BR112017026142A2 publication Critical patent/BR112017026142A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

polipetídeos e métodos para a sua utilização são revelados que têm uma sequência de aminoácidos com pelo menos 75% de identidade à sequência de aminoácidos de seq id no: 1, em que (a) o polipeptídeo degrada um peptídeo pfqpqlpy (seq id no: 140) e/ou um pfpqpqqpf (seq id no: 68) a ph 4; (b) o resíduo 467 é ser, o resíduo 267 é glu, e o resíduo 271 é asp; e (c) o polipeptídeo compreende uma alteração de aminoácido de seq id no: 1 em um ou mais resíduos selecionados do grupo que consiste em 221, 262e, 268, 269, 270, 319a, 320, 354e/q/r/y, 358s/q/t, 368f/q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174 e 456.
BR112017026142A 2015-06-08 2016-06-08 composições e métodos para tratar doença sprue celíaca BR112017026142A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172557P 2015-06-08 2015-06-08
PCT/US2016/036356 WO2016200880A1 (en) 2015-06-08 2016-06-08 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
BR112017026142A2 true BR112017026142A2 (pt) 2018-08-14

Family

ID=56194586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026142A BR112017026142A2 (pt) 2015-06-08 2016-06-08 composições e métodos para tratar doença sprue celíaca

Country Status (24)

Country Link
US (4) US10793846B2 (pt)
EP (1) EP3302518A1 (pt)
JP (3) JP7325030B2 (pt)
KR (1) KR20180023903A (pt)
CN (1) CN107873053A (pt)
AU (2) AU2016276436B2 (pt)
BR (1) BR112017026142A2 (pt)
CA (1) CA2988651A1 (pt)
CL (2) CL2017003097A1 (pt)
CO (1) CO2017013720A2 (pt)
CR (1) CR20170567A (pt)
DO (1) DOP2017000286A (pt)
EA (1) EA037603B1 (pt)
EC (1) ECSP17080844A (pt)
HK (1) HK1245129A1 (pt)
IL (2) IL256103B (pt)
MX (2) MX2017015786A (pt)
MY (1) MY189160A (pt)
PE (1) PE20180509A1 (pt)
PH (1) PH12017502213A1 (pt)
SA (1) SA517390479B1 (pt)
SG (1) SG10201911867YA (pt)
TN (1) TN2017000520A1 (pt)
WO (1) WO2016200880A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6517204B2 (ja) 2013-08-14 2019-05-22 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション セリアックスプルー病を処置するための組成物および方法
EP3302518A1 (en) * 2015-06-08 2018-04-11 University of Washington Compositions and methods for treating celiac sprue disease
CN109414502A (zh) 2016-06-12 2019-03-01 千禧制药公司 治疗炎症性肠病的方法
KR20230107898A (ko) 2016-12-22 2023-07-18 에베 누트리찌온 게엠베하 안정한 프로테아제 변이체
AR123961A1 (es) 2020-10-30 2023-01-25 Univ Washington Composiciones y métodos para el tratamiento de la celiaquía
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7268911B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
WO2003096979A2 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
JP2012500263A (ja) 2008-08-21 2012-01-05 アルヴィン ファーマシューティカルズ インコーポレーティッド タンパク質の経口投与のための製剤
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
US20110200574A1 (en) * 2010-02-02 2011-08-18 Jolly James F Use of proteases for gluten intolerance
EP4023243A3 (en) 2011-08-10 2022-09-14 University of Washington through its Center for Commercialization Compositions and methods for treating celiac sprue disease
WO2013083338A1 (en) 2011-12-06 2013-06-13 Fondazione Istituto Insubrico Di Ricerca Per La Vita New proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus
JP6517204B2 (ja) 2013-08-14 2019-05-22 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション セリアックスプルー病を処置するための組成物および方法
JP6689199B2 (ja) * 2013-08-30 2020-04-28 モーメンティブ・パフォーマンス・マテリアルズ・インク アミノ酸を含む湿気硬化性化合物
EP3302518A1 (en) * 2015-06-08 2018-04-11 University of Washington Compositions and methods for treating celiac sprue disease

Also Published As

Publication number Publication date
KR20180023903A (ko) 2018-03-07
AU2016276436B2 (en) 2022-07-07
US20210171928A1 (en) 2021-06-10
JP2024041995A (ja) 2024-03-27
JP7429907B2 (ja) 2024-02-09
SG10201911867YA (en) 2020-01-30
CL2017003097A1 (es) 2018-06-29
MX2022005483A (es) 2022-06-02
PE20180509A1 (es) 2018-03-09
CA2988651A1 (en) 2016-12-15
US10988748B2 (en) 2021-04-27
MY189160A (en) 2022-01-29
AU2016276436A1 (en) 2017-12-07
EA037603B1 (ru) 2021-04-20
CN107873053A (zh) 2018-04-03
EA201792362A1 (ru) 2018-05-31
US11485961B2 (en) 2022-11-01
IL256103B (en) 2022-01-01
TN2017000520A1 (en) 2019-04-12
US10793846B2 (en) 2020-10-06
JP2021151250A (ja) 2021-09-30
IL288768A (en) 2022-02-01
JP7325030B2 (ja) 2023-08-14
HK1245129A1 (zh) 2018-08-24
DOP2017000286A (es) 2018-03-30
CR20170567A (es) 2018-06-14
US20180142226A1 (en) 2018-05-24
US20230130764A1 (en) 2023-04-27
CL2023000752A1 (es) 2024-04-12
SA517390479B1 (ar) 2022-11-10
IL256103A (en) 2018-02-28
CO2017013720A2 (es) 2018-04-10
MX2017015786A (es) 2018-12-11
PH12017502213A1 (en) 2018-06-11
EA201792362A8 (ru) 2018-12-28
US20200109387A1 (en) 2020-04-09
JP2018517409A (ja) 2018-07-05
AU2022241520A1 (en) 2022-10-27
WO2016200880A1 (en) 2016-12-15
EP3302518A1 (en) 2018-04-11
ECSP17080844A (es) 2018-03-31

Similar Documents

Publication Publication Date Title
BR112017026142A2 (pt) composições e métodos para tratar doença sprue celíaca
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
BR112017026523A2 (pt) vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
BR112017003472A2 (pt) anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
PE20181956A1 (es) Polipeptidos que inhiben cd40l
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112019003462A2 (pt) proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
BR112017022715A2 (pt) variante do polipeptídeo gal-1, ácido nucleico, composição farmacêutica, método para modular uma resposta imunológica e método para tratamento de um sujeito
MY194322A (en) Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
BR112016017388A2 (pt) proteína
EA201792648A1 (ru) Аденовирусные полинуклеотиды и полипептиды

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]